Sagt die FDA doch ja ....

und inwieweit ein R/S durchgeführt wird.

um welches Unternehmen handelt es sich?

das den Krebs besiegt???

Danke im voraus.

größten Beitrag zur Forschung leistet.
Die Fachliteratur ist da sehr eindeutig mit den Hinweisen.

0,0001 $ 84.399 93.799 0,0001 - 0,0001

immernoch leute die hier investiert sind. Dauraus werd ich nicht schlau

Ergebnisse

Die G3139/Electroporation kombinierten Therapie zu einer signifikanten Hemmung des Tumorwachstums (TWI, mehr als 50%) mit einer deutlichen Tumor Nachwachsen Verzögerung (TRD, ca. 20 Tage) begleitet. Die Wirksamkeit dieser Behandlung war aufgrund der höheren G3139 Aufnahme in Tumorzellen, die zu einer merklichen Herabregulation von bcl-2-Protein-Expression führte. Darüber hinaus führte die Kombination G3139/EP Behandlung in einer verstärkten Apoptose-Index und einer verminderten Proliferationsrate von Tumoren. Schließlich wurde ein erhöhtes Ansprechen des Tumors nach der Behandlung mit der Dreierkombination G3139/DDP/EP beobachtet, die einen TWI von etwa 75% und TRD von 30 Tagen.

www.ncbi.nlm.nih.gov/pmc/articles/PMC3163203/

clinicaltrials.gov/ct2/show/results/...k=22&sect=X0125#all

Interessenten an der Ausschlachtung interessiert sind. Dadurch, das Genta Chapter 7 beantragt hat, wird von Seiten des Trustees versucht, z.B. die Verträge, die Genta eingegangen ist, auf Werthaltigkeit zu prüfen. Ich denke, dass einige Interessenten daran interessiert sind, in diese Verträge einzustiegen, weil sie das Potential kennen.
Von den Verhandlungen des Trustees mit den Interessenten hängt der Fortgang ab. Am Freitag war wohl wieder mal ein Gerichtstermin, an dem geprüft wurde, was der Trustee an Ergebnissen vorzuweisen hat, und inwieweit das Gericht Chapter 7 noch verlängern soll.

mit Genasense zu tun, so wie Raurunter in Posting #589 auf einige Studien damit hinweist.

01/25/2013 63 Schedules/Statements filed: Sch A, Sch B, Sch D, Sch E, Sch F, Sch G, Sch H, , Sum of Schs,. Filed by George L. Miller. (Carroll, John) (Entered: 01/25/2013)
01/25/2013 64 Schedules/Statements filed: , , Stmt of Financial Affairs,. Filed by George L. Miller. (Carroll, John) (Entered: 01/25/2013)
01/30/2013 65 Second Motion to Extend Time to Assume or Reject Executory Contracts and Unexpired Leases of Personal Property Pursuant to 11 U.S.C. Section 365(d)(1) Filed by George L. Miller. Hearing scheduled for 3/8/2013 at 02:00 PM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. Objections due by 3/1/2013. (Attachments: # 1 Notice # 2 Proposed Form of Order) (Fraser, Simon) (Entered: 01/30/2013)
02/13/2013 66 The Collins V. Warrell Defendants' Motion for Relief from Stay to Authorize Payment of Loss, Including Defense Costs and the Settlement Amount, from Insurance Proceeds. Fee Amount $176. Filed by Douglas G. Watson, Daniel D. Von Hoff, Christopher P. Parios, Martin J. Driscoll, Gary Siegel, Loretta M. Itri, Raymond P. Warrell, Jr.. Hearing scheduled for 2/27/2013 at 03:00 PM at US Bankruptcy Court, 824 Market St., Wilmington, DE. Objections due by 2/20/2013. (Attachments: # 1 Notice # 2 Proposed Form of Order # 3 Certificate of Service) (Connolly, Colm) Modified text on 2/14/2013 (SJS). (Entered: 02/13/2013)
02/13/2013 67 Receipt of filing fee for Motion for Relief From Stay (B)(12-12269-KG) [motion,mrlfsty] ( 176.00). Receipt Number 6410267, amount $ 176.00. (U.S. Treasury) (Entered: 02/13/2013)
02/13/2013 68 Exhibit(s) A to The Collins v. Warrell Defendants' Motion for Relief from the Bankruptcy Stay to Authorize Payment of Loss, Including Defense Costs and the Settlement Amount, from Insurance Proceeds (related document(s)66) Filed by Martin J. Driscoll, Loretta M. Itri, Christopher P. Parios, Gary Siegel, Daniel D. Von Hoff, Raymond P. Warrell, Jr., Douglas G. Watson. (Connolly, Colm) (Entered: 02/13/2013)
02/13/2013 69 Notice of Hearing (related document(s)66) Filed by Martin J. Driscoll, Loretta M. Itri, Christopher P. Parios, Gary Siegel, Daniel D. Von Hoff, Raymond P. Warrell, Jr., Douglas G. Watson. Hearing scheduled for 2/27/2013 at 03:00 PM at US Bankruptcy Court, 824 Market St., Wilmington, DE. Objections due by 2/20/2013. (Connolly, Colm) (Entered: 02/13/2013)
02/25/2013 70 Certificate of No Objection Regarding the Collins V. Warrell Defendants' Motion for Relief from the Bankruptcy Stay to Authorize Payment of Loss, Including Defense Costs and the Settlement Amount, from Insurance Proceeds (related document(s)66). Filed by Martin J. Driscoll, Loretta M. Itri, Christopher P. Parios, Gary Siegel, Daniel D. Von Hoff, Raymond P. Warrell, Jr., Douglas G. Watson. (Connolly, Colm) Modified text on 2/26/2013 (SJS). (Entered: 02/25/2013)
02/25/2013 71 Notice of Agenda of Matters Scheduled for Hearing Filed by George L. Miller. Hearing scheduled for 2/27/2013 at 03:00 PM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. (Carroll, John) (Entered: 02/25/2013)
02/25/2013 72 Order Authorizing Payment of Loss, Including Defense Costs and the Settlement Amount, from Insurance Proceeds (related document(s)66) Order Signed on 2/25/2013. (SB) (Entered: 02/25/2013)
02/25/2013 73 Amended HEARING CANCELLED/RESCHEDULED. Notice of Agenda of Matters Scheduled for Hearing. Filed by George L. Miller. Hearing scheduled for 2/27/2013 at 03:00 PM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. (Carroll, John) (Entered: 02/25/2013)
03/06/2013 74 Certificate of No Objection Regarding Trustees Second Motion for Entry of Order Further Extending Time to Assume or Reject Executory Contracts and Unexpired Leases of Personal Property Pursuant to 11 U.S.C. Section 365(d)(1) (related document(s)65) Filed by George L. Miller. (Carroll, John) (Entered: 03/06/2013)
03/06/2013 75 Notice of Agenda of Matters Scheduled for Hearing Filed by George L. Miller. Hearing scheduled for 3/8/2013 at 02:00 PM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. (Carroll, John) (Entered: 03/06/2013)
03/06/2013 76 Amended HEARING CANCELLED/RESCHEDULED. Notice of Agenda of Matters Scheduled for Hearing. Filed by George L. Miller. Hearing scheduled for 3/8/2013 at 02:00 PM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. (Carroll, John) (Entered: 03/06/2013)
03/06/2013 77 Order Granting Trustee's Second Motion for Entry of Order Further Extending Time to Assume or Reject Executory Contracts and Unexpired Leases of Personal Property (related document(s)65) Order Signed on 3/6/2013. (SB) (Entered: 03/06/2013)
03/13/2013 78 Application to Employ/Retain Cozen O'Connor as Counsel to the Trustee Filed by George L. Miller. Hearing scheduled for 4/12/2013 at 10:00 AM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. Objections due by 4/5/2013. (Attachments: # 1 Notice # 2 Proposed Form of Order # 3 Affidavit) (Carroll, John) (Entered: 03/13/2013)
03/25/2013 79 Certificate of Service Regarding Application of Chapter 7 Trustee, George L. Miller to Employ Cozen O'Connor as Counsel to the Trustee Nunc Pro Tunc (related document(s)78) Filed by George L. Miller. (Carroll, John) (Entered: 03/25/2013)
03/26/2013 80 Application to Employ/Retain Apto Solutions Inc. as Sales Agent & Computer Professional Filed by George L. Miller. Hearing scheduled for 4/12/2013 at 10:00 AM at US Bankruptcy Court, 824 Market St., 6th Fl., Courtroom #3, Wilmington, Delaware. Objections due by 4/5/2013. (Attachments: # 1 Notice # 2 Proposed Form of Order # 3 Exhibit A# 4 Exhibit B) (Carroll, John) (Entered: 03/26/2013

raurunter's Posting #589 mal genauer betrachten und die dort genannten Ergebnisse sequenzweise analysieren.
Gleich vorweg: Alles ohne Gewähr.

unter dem Titel "Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer". Die Studie selbst ist recht klein, was aber nicht heisst, dass ihre Ergebnisse nicht extrapolierbar wären, und man daraus nicht richtungsweisende Schlussfolgerungen machen kann.
Insbesondere sind solche Stuedien mit kleinem Teilnehmernehmerkreis durchaus geeignet, das Potential einer Verbindung abzuschätzen.

die notwendigen Rechte innehat.
Kurzinformationen hier:
en.wikipedia.org/wiki/Oblimersen
www.ncbi.nlm.nih.gov/pmc/articles/PMC2376092/

Und eine sehr wichtige Übersicht hier:
www.fda.gov/ohrms/dockets/ac/06/briefing/...nta-background.pdf